Cholinesterase Inhibitors

"Cholinesterase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

Descriptor ID	D002800
MeSH Number(s)	D27.505.519.389.275 D27.505.519.625.120.300 D27.505.696.577.120.300
Concept/Terms	Cholinesterase Inhibitors Cholinesterase Inhibitors Inhibitors, Cholinesterase Anticholinesterase Drugs Drugs, Anticholinesterase Anticholinesterases Anticholinesterase Agents Agents, Anticholinesterase Anti-Cholinesterases Anti Cholinesterases Cholinesterase Inhibitors, Irreversible Cholinesterase Inhibitors, Irreversible Inhibitors, Irreversible Cholinesterase Irreversible Cholinesterase Inhibitors Cholinesterase Inhibitors, Reversible Cholinesterase Inhibitors, Reversible Inhibitors, Reversible Cholinesterase Reversible Cholinesterase Inhibitors Acetylcholinesterase Inhibitors Acetylcholinesterase Inhibitors Inhibitors, Acetylcholinesterase

Below are MeSH descriptors whose meaning is more general than "Cholinesterase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Cholinesterase Inhibitors [D27.505.519.389.275]
Neurotransmitter Agents [D27.505.519.625]
Cholinergic Agents [D27.505.519.625.120]
Cholinesterase Inhibitors [D27.505.519.625.120.300]
Physiological Effects of Drugs [D27.505.696]
Neurotransmitter Agents [D27.505.696.577]
Cholinergic Agents [D27.505.696.577.120]
Cholinesterase Inhibitors [D27.505.696.577.120.300]

Below are MeSH descriptors whose meaning is related to "Cholinesterase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Cholinesterase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Cholinesterase Inhibitors" by people in this website by year, and whether "Cholinesterase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 31 publications over 21 distinct years, with a maximum of 2 publications in 1998 and 2001 and 2002 and 2006 and 2007 and 2008 and 2010 and 2013 and 2020 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1997	1	0	1
1998	1	1	2
2001	0	2	2
2002	2	0	2
2003	1	0	1
2004	0	1	1
2005	1	0	1
2006	1	1	2
2007	1	1	2
2008	2	0	2
2009	0	1	1
2010	2	0	2
2011	1	0	1
2013	1	1	2
2015	0	1	1
2017	0	1	1
2020	1	1	2
2021	1	0	1
2022	1	0	1
2023	0	1	1
2024	1	1	2

Below are the most recent publications written about "Cholinesterase Inhibitors" by people in Profiles.

Dalton J, Heard J, Huang R, Ezeonu O, Nardone B, Dwosh R, Kepler CK. Neuromuscular Blockade Reversal With Sugammadex Reduces Cardiac Complications and OR Time for Prone Lumbar Spinal Fusion Compared With Neostigmine. Spine (Phila Pa 1976). 2025 Oct 01; 50(19):1342-1348.

View in: PubMed
Arciniegas DB, Almeida EJ, Sander AM, Bogaards JA, Giacino JT, Hammond FM, Harrison-Felix CL, Hart T, Ketchum JM, Mellick DC, Sherer M, Whyte J, Zafonte RD. Multicenter Evaluation of Memory Remediation in Traumatic Brain Injury With Donepezil: A Randomized Controlled Trial. J Neuropsychiatry Clin Neurosci. 2025; 37(2):102-114.

View in: PubMed
Massoudi N, Mohit B, Fathi M, Nooraei N, Hannani KK, ArianNik M. The impact of rivastigmine on post-surgical delirium and cognitive impairment; a randomized clinical trial. Int J Geriatr Psychiatry. 2023 07; 38(7):e5970.

View in: PubMed
Isaac E, Ney D, Serruya M, Keith S, Lippa C, Sperling MR. Tolerability of memantine monotherapy versus adding memantine as combination therapy. J Natl Med Assoc. 2022 Jun; 114(3):308-313.

View in: PubMed
Llad? A, Froelich L, Khandker RK, Roset M, Black CM, Lara N, Chekani F, Ambegaonkar BM. Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries. J Alzheimers Dis. 2021; 80(2):749-759.

View in: PubMed
Goldman JG, Forsberg LK, Boeve BF, Armstrong MJ, Irwin DJ, Ferman TJ, Galasko D, Galvin JE, Kaufer D, Leverenz J, Lippa CF, Marder K, Abler V, Biglan K, Irizarry M, Keller B, Munsie L, Nakagawa M, Taylor A, Graham T. Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials. Alzheimers Res Ther. 2020 10 29; 12(1):137.

View in: PubMed
Anwar F, Saleem U, Ahmad B, Ashraf M, Rehman AU, Froeyen M, Kee LY, Abdullah I, Mirza MU, Ahmad S. New naphthalene derivative for cost-effective AChE inhibitors for Alzheimer's treatment: In silico identification, in vitro and in vivo validation. Comput Biol Chem. 2020 Dec; 89:107378.

View in: PubMed
Fink HA, Jutkowitz E, McCarten JR, Hemmy LS, Butler M, Davila H, Ratner E, Calvert C, Barclay TR, Brasure M, Nelson VA, Kane RL. Pharmacologic Interventions to Prevent Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer-Type Dementia: A Systematic Review. Ann Intern Med. 2018 01 02; 168(1):39-51.

View in: PubMed
Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EG. Donepezil for Irradiated Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. J Clin Oncol. 2015 May 20; 33(15):1653-9.

View in: PubMed
Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. Dronabinol for the treatment of agitation and aggressive behavior in acutely hospitalized severely demented patients with noncognitive behavioral symptoms. Am J Geriatr Psychiatry. 2014 Apr; 22(4):415-9.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement